Skip to content

A Real-World Registry Study of Repeated Low-Level Red-Light Therapy in Children With Myopia Showing Poor Response to Conventional Treatment

A Real-World Registry Study of Repeated Low-Level Red-Light Therapy in Children With Myopia Showing Poor Response to Conventional Treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126300
Enrollment
Unknown
Registered
2026-06-05
Start date
2025-04-20
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Interventions

Defocus Incorporated Multiple Segments Spectacle Lenses Combined with Repeated Low-Level Red-Light Therapy (RLRL) (DCR) group:In the RCD groups followed the same lens-wearing schedule and additionally
Orthokeratology (RCO) Combined with Repeated Low-Level Red-Light Therapy (RLRL) group:Participants will wear orthokeratology (OK) lenses for at least 10 hours every night and concurrently receive rep

Sponsors

Affiliated Hospital of North Sichuan Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
8 Years to 16 Years

Inclusion criteria

Inclusion criteria: 1. Age: 8 to 16 years at the time of data collection, meeting the standard requirements for RLRL devices; 2. Diagnosis: Diagnosed with myopia and having received conventional myopia treatments (including orthokeratology, multifocal/defocus spectacles or their equivalents, or 0.01%/0.05% atropine eye drops) for at least six months. Eligible patients must demonstrate inadequate control of myopia progression, defined as an axial length increase of >=0.3 mm per year or a spherical equivalent refraction (SER) progression of >=0.5 D per year; 3. Best-corrected visual acuity (BCVA): 20/20 or better; 4. Treatment: Data from patients who have received or are planning to receive red light therapy as a strategy for myopia management.

Exclusion criteria

Exclusion criteria: 1. Presence of ocular diseases other than refractive errors, including but not limited to strabismus and binocular vision abnormalities; 2. Presence of systemic diseases (such as endocrine disorders, cardiovascular diseases) or developmental abnormalities; 3. Concurrent use of atropine eye drops together with RLRL treatment.

Design outcomes

Primary

MeasureTime frame
Axial length, AL;

Secondary

MeasureTime frame
Spherical equivalent refraction, SER;Choroidal thickness below the macular fovea;

Countries

China

Contacts

Public ContactQingqing Tan

Department of Ophthalmology, Affiliated Hospital of North Sichuan Medical College

tqq0720@126.com+86 138 9083 4742

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026